Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSE | P14091 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569650 | 1.00 | RORC (0.37) | RORCHDAC1MIFNPC1RECQL | |
| SCHEMBL10255921 | 1.00 | RORC (0.37) | RORCHDAC1MIFNPC1RECQL | |
| SCHEMBL569912 | 0.86 | RORC (0.38) | RORCHDAC1MIFNPC1RECQL | |
| SCHEMBL569914 | 0.86 | RORC (0.38) | RORCHDAC1MIFNPC1RECQL | |
| SCHEMBL569913 | 0.86 | RORC (0.38) | RORCHDAC1MIFNPC1RECQL | |
| SCHEMBL569495 | 0.86 | RORC (0.39) | RORCHDAC1CTSDCTSEBACE1 | |
| SCHEMBL18587858 | 0.80 | RORC (0.40) | RORCSMN1; SMN2CTSDCTSEBACE1 | |
| SCHEMBL569652 | 0.80 | RORC (0.54) | RORCCTSDCTSEBACE1 | |
| SCHEMBL15223009 | 0.80 | RORC (0.50) | RORCTACR1 | |
| SCHEMBL15155806 | 0.79 | GPR119 (0.50) | RORCNPC1CTSDCTSEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2601190-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | AH USA 42 LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | RORC 519/4885HDAC1 1574/4885MIF 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.